Effectiveness and tolerability of mirtazapine and amitriptyline in alcoholic patients with co-morbid depressive disorder: A randomized, double-blind study

Basit Öğe Kaydı
dc.contributor.authorAltintoprak A.E.
dc.contributor.authorZorlu N.
dc.contributor.authorCoskunol H.
dc.contributor.authorAkdeniz F.
dc.contributor.authorKitapcioglu G.
dc.date.accessioned2019-10-26T23:57:29Z
dc.date.available2019-10-26T23:57:29Z
dc.date.issued2008
dc.departmentEge Üniversitesien_US
dc.description.abstractObjective: Studies indicate that serotoninergic and noradrenergic pathophysiological mechanisms may underlie both alcohol abuse/dependence and depressive disorder. The purpose of this study was to evaluate and compare the effectiveness and tolerability of two serotonergic and noradrenergic antidepressant drugs-mirtazapine and amitriptyline, for the treatment of patients with alcohol dependence co-morbid with depressive disorder in a randomized, double-blind treatment setting. Methods: Forty-four patients were included in the study. Twenty-four patients were randomized to mirtazapine and twenty to amitriptyline groups. Thirty-six of them completed the study. The 17-item Hamilton Depression Rating Scale (HDRS), the Spielberger State-Trait Anxiety Inventory (STAI) and alcohol craving questionnaire were used at baseline and, at days 7, 14, 28, 42, and 56 to estimate the effectiveness of the antidepressant treatment. Michigan Alcoholism Screening Test (MAST) was used in the assessment of alcohol dependence. The tolerability was assessed with the Udvalg for Kliniske Undersogelser Side Effect Rating Scale (UKU). Results: There was significant improvement in HDRS and alcohol craving scores with both the drugs. However there were no statistical differences between treatment groups. Mirtazapine was tolerated better than amitriptyline treatment. Conclusions: The treatment with either mirtazapine or amitriptyline resulted with the reduction of HDRS and craving scores. The side-effect profile of mirtazapine was relatively favorable in our study. Copyright © 2008 John Wiley & Sons, Ltd.en_US
dc.identifier.doi10.1002/hup.935en_US
dc.identifier.endpage319en_US
dc.identifier.issn0885-6222
dc.identifier.issue4en_US
dc.identifier.pmid18327889en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage313en_US
dc.identifier.urihttps://doi.org/10.1002/hup.935
dc.identifier.urihttps://hdl.handle.net/11454/21028
dc.identifier.volume23en_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.relation.ispartofHuman Psychopharmacologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAlcohol dependenceen_US
dc.subjectAmitriptylineen_US
dc.subjectCo-morbidityen_US
dc.subjectDepressive disorderen_US
dc.subjectMirtazapineen_US
dc.titleEffectiveness and tolerability of mirtazapine and amitriptyline in alcoholic patients with co-morbid depressive disorder: A randomized, double-blind studyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu